Apogee Therapeutics (NASDAQ:APGE) Sets New 1-Year High – Still a Buy?

Apogee Therapeutics Inc. (NASDAQ:APGE) shares reached a new 52-week high during mid-day trading on Thursday . The stock traded as high as $85.04 and last traded at $78.53, with a volume of 3533056 shares traded. The stock had previously closed at $73.00.

Key Apogee Therapeutics News

Here are the key news stories impacting Apogee Therapeutics this week:

• Positive Sentiment: Positive 52‑week Phase II Part A results for zumilokibart showing sustained, durable responses and attractive infrequent dosing — data cited as boosting the drug’s commercial promise and near‑term clinical catalysts (Part B 16‑week induction data in Q2; potential Phase 3 in H2 2026). Zacks: APGE Stock Up as Skin Disease Drug Shows Sustained 52-Week Efficacy
• Positive Sentiment: Investor enthusiasm reinforced by buy‑side commentary and bullish coverage calling APGE a “Strong Buy” ahead of upcoming readouts and potential Phase 3 start. Seeking Alpha highlights the program’s extended‑half‑life profile and upcoming catalysts. Seeking Alpha: Strong Buy
• Positive Sentiment: Several firms raised price targets and maintained buy ratings (Citigroup, Canaccord, Guggenheim), increasing upside estimates and supporting near‑term investor optimism. Benzinga: Analyst Coverage TickerReport: Guggenheim Raise
• Neutral Sentiment: Reported short‑interest data appears anomalous (entries showing 0 shares and NaN changes across multiple reports), so there’s no clear short‑pressure signal to explain price moves; treat the short‑interest items as unreliable until clarified.
• Negative Sentiment: Apogee priced an underwritten public offering of 5,000,000 shares at $70.00 (aggregate gross proceeds ~$350M) with a 30‑day option for up to 750,000 additional shares — this raises cash and extends runway but is dilutive and was priced below the current market, which can cap near‑term upside. Closing expected March 26, subject to conditions. GlobeNewswire: Offering Announcement MSN: Offering Coverage

Analysts Set New Price Targets

Several research firms have weighed in on APGE. Citigroup boosted their price target on Apogee Therapeutics from $95.00 to $125.00 and gave the stock a “buy” rating in a research report on Tuesday. Jefferies Financial Group reaffirmed a “buy” rating and set a $95.00 price target on shares of Apogee Therapeutics in a research report on Monday, February 2nd. Deutsche Bank Aktiengesellschaft initiated coverage on shares of Apogee Therapeutics in a research report on Tuesday, December 9th. They issued a “buy” rating and a $103.00 price objective for the company. UBS Group raised shares of Apogee Therapeutics to a “strong-buy” rating in a report on Wednesday, January 7th. Finally, Wall Street Zen cut Apogee Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, December 6th. Three analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating, four have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Apogee Therapeutics has a consensus rating of “Moderate Buy” and a consensus price target of $110.43.

Apogee Therapeutics Price Performance

The company’s 50-day moving average price is $71.09 and its two-hundred day moving average price is $64.05. The company has a market capitalization of $5.46 billion, a P/E ratio of -18.61 and a beta of 1.39.

Apogee Therapeutics (NASDAQ:APGE) last announced its earnings results on Monday, March 2nd. The company reported ($1.03) EPS for the quarter, topping the consensus estimate of ($1.05) by $0.02. On average, analysts anticipate that Apogee Therapeutics Inc. will post -3.09 earnings per share for the current fiscal year.

Insider Transactions at Apogee Therapeutics

In other Apogee Therapeutics news, Director Fairmount Funds Management Llc sold 1,750,000 shares of the company’s stock in a transaction on Thursday, January 22nd. The stock was sold at an average price of $76.30, for a total value of $133,525,000.00. Following the transaction, the director directly owned 298,647 shares of the company’s stock, valued at $22,786,766.10. This represents a 85.42% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, CEO Michael Thomas Henderson sold 20,000 shares of Apogee Therapeutics stock in a transaction on Wednesday, March 11th. The stock was sold at an average price of $74.78, for a total value of $1,495,600.00. Following the sale, the chief executive officer directly owned 1,152,987 shares of the company’s stock, valued at $86,220,367.86. This represents a 1.71% decrease in their position. The SEC filing for this sale provides additional information. Over the last quarter, insiders have sold 1,839,700 shares of company stock worth $140,118,083. Company insiders own 42.77% of the company’s stock.

Institutional Trading of Apogee Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of the business. Rockefeller Capital Management L.P. acquired a new position in shares of Apogee Therapeutics during the 4th quarter worth approximately $25,000. Los Angeles Capital Management LLC bought a new stake in shares of Apogee Therapeutics in the fourth quarter valued at approximately $37,000. ANTIPODES PARTNERS Ltd boosted its stake in shares of Apogee Therapeutics by 41.2% in the third quarter. ANTIPODES PARTNERS Ltd now owns 843 shares of the company’s stock valued at $33,000 after buying an additional 246 shares during the period. Seven Fleet Capital Management LP acquired a new stake in Apogee Therapeutics during the fourth quarter worth approximately $136,000. Finally, Ensign Peak Advisors Inc acquired a new stake in Apogee Therapeutics during the fourth quarter worth approximately $170,000. Institutional investors and hedge funds own 79.04% of the company’s stock.

Apogee Therapeutics Company Profile

Apogee Therapeutics, Inc is a clinical-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics that selectively target the nuclear receptor RORγt, a master regulator of T cell-driven inflammatory pathways. By modulating RORγt activity, Apogee aims to offer an oral treatment option for patients with autoimmune and inflammatory skin disorders.

The company’s lead candidate, APG-157, is an oral RORγt inverse agonist currently undergoing early-stage clinical evaluation for moderate to severe plaque psoriasis.